Board of Directors

Kozak Kevin R. Kozak, M.D., Ph.D.
Co-Founder and Chief Medical Officer
Dr. Kozak is the Chief of Radiation Oncology at Mercy Regional Cancer Center. Dr. Kozak is an Honorary Fellow in the Department of Medical Physics at the University of Wisconsin-Madison. He also was an Assistant Professor in the Department of Human Oncology at the University of Wisconsin-Madison (2008-13). He served as Chief Medical Officer for Cellectar Biosciences (2013-2016). He is a Board Certified Radiation Oncologist from the American Board of Radiology. Dr. Kozak earned his Ph.D. in Biochemistry and M.D. degree from Vanderbilt University and completed a post-doctoral fellowship and radiation oncology clinical training at the Harvard Radiation Oncology Program.
gskwon Glen S. Kwon, Ph.D.
Co-Founder and Chief Scientific Officer

Prof. Kwon is a faculty member at the University of Wisconsin-Madison where he holds the Jens T. Carstensen Distinguished Chair at the School of Pharmacy. He is a member of the Experimental Therapeutics Program at the UW-Madison Carbone Cancer Center, an Adjunct Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta and a member of the Board of Scientific Advisors in CRS. He is a Fellow of the American Association of Pharmaceutical Scientists (2012). Prof. Kwon was a Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellow at the Institute of Advanced Biomedical Engineering and Science at Tokyo Women’s Medical University in Tokyo, Japan from 1991 to 1993 and an Assistant Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta in Edmonton, Canada from 1993 to 1997. He received the Jorge Heller Journal of Controlled Release/Controlled Release Society (CRS) Outstanding Paper Award in 1994 and the CRS Young Investigator Research Achievement Award in 2003. He was the editor of Polymeric Drug Delivery Systems in 2005 and co-editor of Nanotechnology in Drug Delivery in 2008. He served on the Gene and Drug Delivery Study Section at NIH from 2005 to 2009. Dr. Kwon served as a Consultant at Nanocarrier Inc., PhaseRx and Intezyne.
Abdalla A. Saad
Mr. Saad has been instrumental in launching Co-D Therapeutics where he is involved in business development, fund raising, and technology licensing. He assisted in securing funding through WARF’s Accelerator Program to develop Triolimus. Prior to Co-D, Mr. Saad held positions as a research scientist at the University of Wisconsin-Madison where he developed expertise in drug screening techniques and technology evaluation. Mr. Saad has worked for both the Wisconsin Entrepreneurs’ Network and the Venture Capital Group at Burrill & Company. Mr. Saad received his B.S. in Zoology and M.S. in Biotechnology from the University of Wisconsin-Madison.

J. Patrick Genn
Co-Founder, President and CEO of Archeus Technologies, Inc.
Mr. Genn is the Co-Founder, President and CEO of Archeus Technologies, Inc. Prior to Archeus, he served as Vice President, Business Development at Cellectar Biosciences. Mr. Genn has over 30 years of senior management experience in early-stage biotechs, finance, banking and investment management. Mr. Genn was previously President of Continuum Investment Holdings, Inc., from 2006 through mid-2010 while serving on the Board of Directors of several biotech and technology companies including Cellectar, Inc. From 2001 through 2005, he was an advisor and consultant to several companies including Carmel Valley Ventures and Continuum Investment Partners. Mr. Genn held several senior management positions at Wells Fargo between 1987 and 2001. He was a member of the senior management team that launched the Mortgage Lending division in 1987 and the Premier Banking division in 1993. He was also a member of the core M&A integration team and managed private client services in San Diego, CA. Mr. Genn received a B.B.A. in Marketing and a Master of Science in Product Management from the University of Wisconsin-Madison.

Alex S. Kim, M.A.
Chief Medical Officer, Elevar Therapeutics Inc.
Mr. Kim is a serial entrepreneur with 24 years of experience in the biopharmaceutical industry. During his career, he has focused on serving shareholders and inventors to build enterprise value for high-technology startups, many of which have gone on to become successful publicly-traded entities. He has served in numerous functions at these organizations including; executive management, business development, product and technology licensing, strategic planning, fund raising, and M&A activity. Mr. Kim’s work, as an early risk-taker at venture-stage companies, has contributed directly to the success of such firms which include Theratech, Inc. (now Watson Pharma); VivoRx, Inc. (Abraxis Pharmaceutical Products); Expression Genetics, Inc.; MacroMed, Inc. (now BTG, PLC); and LSK BioPartners, Inc (LSKB). Mr. Kim received a graduate degree in international business from SangJi (Sophia) University in Tokyo, Japan.

Mr. Kim is a founding Board member of LSKB and serves on the management as Executive Vice President overseeing all business functions of the company. Through consulting and with its own pipeline, LSKB is a healthcare products development company that bridges the gap from discovery to early clinical stage.

Paul V. Radspinner
Founder, President and Chief Executive Officer of FluGen Inc.
Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc., a Madison, Wisconsin influenza vaccines company. After completing his MBA at Northwestern University’s Kellogg Graduate School of Management he spent over 15 years in management roles overseeing international pharmaceutical operations, marketing and business development with Eli Lilly and Company. Subsequent to his time at Lilly he managed the pharmaceuticals portfolio including Vitamin D analogs at the Wisconsin Alumni Research Foundation (WARF) for the University of Wisconsin-Madison. Most recently, Mr. Radspinner took on the role of Vice President of Business Development for Deltanoid Pharmaceuticals, Inc. before he started FluGen with Drs. Yoshihiro Kawaoka and Gabriele Neumann in June of 2007. FluGen has raised over $25 million in capital thus far and is slated to initiate phase 2 clinical trials for its universal influenza vaccine candidate in 2018. Mr. Radspinner is a member of the Boards of Directors for Pan Genome Sciences and Co-D Therapeutics Inc.